Anti-PD-1 [5C4.B8 (Nivolumab)]

Absolute Antibody

Anti-PD-1 [5C4.B8 (Nivolumab)]

7

Nivolumab has been shown to bind to PD-1-expressing CHO cells (EC50 ~1.66nM). Nivolumab binds CD4+ T cells (EC50 ~0.64 nM) and stains only memory and effector, and not naiive CD4+ or CD8+ T cells from human peripheral blood by FC. The antibody is able to block the interaction between PD-1 and its ligands PDL-1 and PDL-2 (IC50 ~2.52 nM and ~2.59 nM, respectively - determined by SPR) - these IC50 values are also similar to that measured by FACS to evaluate ligand binding to PD-1 expressed on CHO cells. In an allogenic T-cell/DC MLR, Nivolumab-mediated inhibition of PD-1 results in enhancement of IFNgamma release, and also enhances IL-2 secretion (97-139% over an isotype control) in response to the superantigen SEB using human peripheral blood mononuclear cells. The same is also observed in a CMV-restimulation assay. Nivolumab at very low concentrations (~1.5 ng/mL) is able to enhance T-cell reactivity in the presence of a T-cell receptor stimulus - nivolumab has no stimulatory effect in the absence of antigen or T-cell receptor stimulus. In the therapeutically used human IgG4 (S228P) format, this antibody is unable to mediate ADCC (antibody-dependent cell-mediated cytotoxicity) or CDC (complement-dependent cytotoxicity).

Flow Cytometry, ImmunoHistoChemistry, Neutralisation/Blocking, Other Application

IHC; FC; SPR; block

Research Use Only

Monoclonal

5C4.B8 (Nivolumab)

PDCD1

programmed cell death 1

CD279; hPD-1; hPD-l; hSLE1; PD1; PD-1; programmed cell death 1 protein; programmed cell death protein 1; protein PD-1; SLEB2; systemic lupus erythematosus susceptibility 2

Mouse

IgG1

Programmed cell death protein 1

This chimeric mouse antibody was made using the variable domain sequences of the original human IgG4 (S228P) format, for improved compatibility with existing reagents, assays and techniques. NOT FOR THERAPEUTIC USE- This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques.

Human, cynomolgus

mAb PD1.5 was prepared by immunizing IgH and IgK knock-out transgenic mice possessing a human immunoglobulin (heavy chain) minilocus with recombinant human PD-1-Fc protein consisting of the extracellular domain of PD-1 (amino acids 1–167) and the Fc portion of human IgG1, and Chinese hamster ovary (CHO) cells expressing human PD-1. Nivolumab was generated by grafting the variable regions of PD1.5 onto human kappa and IgG4 constant regions containing an S228P mutation (prevents Fab arm exchange with endogenous IgG4 antibodies).

-20°C,2°C to 8°C

12352203